Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    Lambert-Eaton Myasthenic Syndrome
Show Display Options
Rank Status Study
1 Available Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
2 Completed A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo
3 No longer available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP
4 No longer available Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Condition: Lambert Eaton Myasthenic Syndrome (LEMS)
Intervention: Drug: 3,4-diaminopyridine
5 Unknown  Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Conditions: Lambert-Eaton Myasthenic Syndrome;   Eaton-Lambert Myasthenic Syndrome
Interventions: Drug: 3,4-DAP;   Drug: 3,4-DAP Taper to Placebo
6 Recruiting 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome
Interventions: Drug: 3,4-DIAMINOPYRIDINE;   Drug: 3,4-Diaminopyridine
7 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
8 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
9 Completed Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-diaminopyridine
10 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
11 Enrolling by invitation Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert-Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo Oral Tablet
12 Available Treatment Use of 3,4-Diaminopyridine
Conditions: Lambert Eaton Myasthenic Syndrome (LEMS);   Myasthenic Syndromes, Congenital
Intervention: Drug: 3,4-diaminopyridine
13 Completed Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Condition: Congenital Myasthenic Syndrome
Intervention: Drug: Albuterol
14 Available Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
15 Recruiting Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Condition: Myasthenic Syndromes, Congenital
Interventions: Drug: amifampridine phosphate;   Drug: Placebo
16 Enrolling by invitation Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
Condition: Muscle Weakness
Intervention: Drug: 3-4 Diaminopyridine
17 Completed Pregnancy Outcomes in Congenital Myasthenie Syndrome
Condition: Congenital Myasthenic Syndrome
Intervention:
18 Enrolling by invitation Ephedrine for the Treatment of Congenital Myasthenia
Condition: Myasthenic Syndromes, Congenital
Intervention: Drug: Ephedrine
19 Recruiting National Registry for Egyptian Pediatric Neuromuscular Diseases
Conditions: Spinal Muscular Atrophy;   Muscular Dystrophy;   Muscle Diseases;   Myasthenic Syndromes;   Polyneuropathies
Intervention:
20 Recruiting Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Conditions: Melanoma;   Lung Cancer
Intervention:

Study has passed its completion date and status has not been verified in more than two years.